Johnson & Johnson's Ottava Robotic Surgery System Gains FDA Clearance, Challenging Intuitive Surgical's Da Vinci

JNJ0.84%
According to reports, Johnson & Johnson received FDA clearance for its Ottava robotic surgery system on Wednesday, July 22, officially entering the robotic surgery market and competing against Intuitive Surgical's da Vinci system and Medtronic's Hugo system. The Ottava system is approved for multiple upper abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, sleeve gastrectomy, appendectomy, and hiatal hernia repair. A key differentiator is that Ottava integrates its robotic arm directly into the surgical table, reducing space requirements by 30% to 50% compared to traditional systems, allowing more operating rooms to adopt robotic surgery technology.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments